These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21349925)

  • 21. Analysis of plasma surfactant protein D levels in lung transplant recipients.
    Bejvl I; Weseslindtner L; Strassl R; Jaksch P; Kundi M; Klepetko W; Puchhammer-Stöckl E
    Transpl Infect Dis; 2013 Dec; 15(6):645-51. PubMed ID: 24028302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Levels of Visfatin, Omentin and Irisin in Patients with End-Stage Lung Disease Before and After Lung Transplantation.
    Ochman M; Maruszewski M; Wojarski J; Żegleń S; Karolak W; Stanjek-Cichoracka A; Przybyłowski P; Zembala M; Kukla M
    Ann Transplant; 2017 Dec; 22():761-768. PubMed ID: 29277835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single Versus Bilateral Lung Transplantation for Idiopathic Pulmonary Fibrosis in the Lung Allocation Score Era.
    Spratt JR; Tomic R; Brown RZ; Rudser K; Loor G; Hertz M; Shumway S; Kelly RF
    J Surg Res; 2019 Feb; 234():84-95. PubMed ID: 30527505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis.
    Nishikiori H; Chiba H; Ariki S; Kuronuma K; Otsuka M; Shiratori M; Ikeda K; Watanabe A; Kuroki Y; Takahashi H
    BMC Pulm Med; 2014 Dec; 14():196. PubMed ID: 25488319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.
    Shah RJ; Bellamy SL; Localio AR; Wickersham N; Diamond JM; Weinacker A; Lama VN; Bhorade S; Belperio JA; Crespo M; Demissie E; Kawut SM; Wille KM; Lederer DJ; Lee JC; Palmer SM; Orens J; Reynolds J; Shah A; Wilkes DS; Ware LB; Christie JD
    J Heart Lung Transplant; 2012 Sep; 31(9):942-9. PubMed ID: 22694851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis.
    Aoshima Y; Enomoto Y; Muto S; Meguro S; Kawasaki H; Kosugi I; Fujisawa T; Enomoto N; Inui N; Nakamura Y; Suda T; Iwashita T
    Lung; 2021 Jun; 199(3):289-298. PubMed ID: 33770226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idiopathic pulmonary fibrosis is associated with increased impedance measures of reflux compared to non-fibrotic disease among pre-lung transplant patients.
    Gavini S; Finn RT; Lo WK; Goldberg HJ; Burakoff R; Feldman N; Chan WW
    Neurogastroenterol Motil; 2015 Sep; 27(9):1326-32. PubMed ID: 26176338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.
    Vuga LJ; Tedrow JR; Pandit KV; Tan J; Kass DJ; Xue J; Chandra D; Leader JK; Gibson KF; Kaminski N; Sciurba FC; Duncan SR
    Am J Respir Crit Care Med; 2014 Apr; 189(8):966-74. PubMed ID: 24628285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung transplant recipients with idiopathic pulmonary fibrosis have impaired alloreactive immune responses.
    Wang P; Leung J; Lam A; Lee S; Calabrese DR; Hays SR; Golden JA; Kukreja J; Singer JP; Wolters PJ; Tang Q; Greenland JR
    J Heart Lung Transplant; 2022 May; 41(5):641-653. PubMed ID: 34924263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation.
    Shah RJ; Diamond JM; Lederer DJ; Arcasoy SM; Cantu EM; Demissie EJ; Kawut SM; Kohl B; Lee JC; Sonett J; Christie JD; Ware LB
    Transl Res; 2012 Dec; 160(6):435-42. PubMed ID: 22989614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation.
    Rusanov V; Kramer MR; Raviv Y; Medalion B; Guber A; Shitrit D
    Chest; 2012 Apr; 141(4):1047-1054. PubMed ID: 21940773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).
    Keller M; Bush E; Diamond JM; Shah P; Matthew J; Brown AW; Sun J; Timofte I; Kong H; Tunc I; Luikart H; Iacono A; Nathan SD; Khush KK; Orens J; Jang M; Agbor-Enoh S
    J Heart Lung Transplant; 2021 Jun; 40(6):488-493. PubMed ID: 33814284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis.
    Hanaka T; Kido T; Noguchi S; Yamada S; Noguchi H; Guo X; Nawata A; Wang KY; Oda K; Takaki T; Izumi H; Ishimoto H; Yatera K; Mukae H
    BMC Pulm Med; 2019 Dec; 19(1):265. PubMed ID: 31888585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study.
    Gershman E; Zer A; Pertzov B; Shtraichman O; Shitenberg D; Heching M; Rosengarten D; Kramer M
    BMJ Open Respir Res; 2020 Jun; 7(1):. PubMed ID: 32565443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.
    Christie JD; Shah CV; Kawut SM; Mangalmurti N; Lederer DJ; Sonett JR; Ahya VN; Palmer SM; Wille K; Lama V; Shah PD; Shah A; Weinacker A; Deutschman CS; Kohl BA; Demissie E; Bellamy S; Ware LB;
    Am J Respir Crit Care Med; 2009 Nov; 180(10):1010-5. PubMed ID: 19661249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplant Outcomes.
    Warrior K; Sayad K; O'Hara CP; Dilling DF
    Transplantation; 2024 Jun; 108(6):1460-1465. PubMed ID: 38291576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations.
    Tiriveedhi V; Gautam B; Sarma NJ; Askar M; Budev M; Aloush A; Hachem R; Trulock E; Myers B; Patterson AG; Mohanakumar T
    J Heart Lung Transplant; 2013 Aug; 32(8):807-14. PubMed ID: 23856218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD.
    Winkler C; Atochina-Vasserman EN; Holz O; Beers MF; Erpenbeck VJ; Krug N; Roepcke S; Lauer G; Elmlinger M; Hohlfeld JM
    Respir Res; 2011 Mar; 12(1):29. PubMed ID: 21396106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.